All the news Showing 9 of 39 articles from: Treatment for previous non-responders & relapsersGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Triple-drug HCV therapy comes with high risk of serious adverse events for people with cirrhosis Keith Alcorn / 30 April 2013 Currently available triple therapies for hepatitis C carry a high risk of serious side-effects for people in the most urgent need of treatment, and these patients have only a moderate chance of being ... Hep C quad regimens quashed, but some components go forward Liz Highleyman / 29 April 2013 A pair of four-drug interferon-based hepatitis C regimens worked well, but further study has been halted after a few patients experienced serious adverse events, according to a set of presentations last week at ... Daclatasvir + sofosbuvir offers hepatitis C rescue therapy after current standard of care Liz Highleyman / 29 April 2013 An interferon-free regimen of daclatasvir plus sofosbuvir, with or without ribavirin, cured all previously treated hepatitis C (HCV) patients who did not respond to interferon-based triple therapy using the approved HCV protease inhibitors ... Hepatitis C patients with cirrhosis respond well to boceprevir or telaprevir with careful monitoring Liz Highleyman / 05 December 2012 Real-world experience in the French early-access CUPIC cohort shows that hepatitis C patients with advanced liver damage can achieve good response to interferon-based triple-therapy including boceprevir (Victrelis) or telaprevir (Incivo), researchers reported ... Sofosbuvir demonstrates high response rate in interferon-free combination with ribavirin and GS-5885 Liz Highleyman / 15 November 2012 The hepatitis C polymerase inhibitor sofosbuvir produced high rates of sustained virological response in genotype 1 patients when combined with ribavirin and the HCV NS5A inhibitor GS-5885, according to data presented this week ... High rate of response to BMS HCV drugs in harder-to-treat patients – but interferon-free prospects differ by sub-genotype Keith Alcorn / 12 November 2012 Although an interferon-free combination of antiviral drugs developed by Bristol-Myers Squibb to treat hepatitis C was highly effective in curing the infection in previous null responders to treatment with HCV genotype 1b infection, ... New hepatitis C drugs danoprevir and mericitabine are safe and effective for prior non-responders and people with cirrhosis Liz Highleyman / 12 November 2012 The experimental hepatitis C drugs danoprevir and mericitabine, with or without pegylated interferon and ribavirin, showed good safety and efficacy in previously treated patients, according to findings from the MATTERHORN study presented at ... Boceprevir a useful option for patients who did not respond to earlier course of hepatitis C therapy Michael Carter / 23 April 2012 A regimen of boceprevir with pegylated interferon and ribavirin achieved cure rates of between 40 and 68% in patients who did not respond to a previous course of hepatitis C therapy, data ... Adding TMC435 boosts response for difficult-to-treat hepatitis C patients Liz Highleyman / 23 April 2012 A combination of TMC435 – also known as simeprevir – plus pegylated interferon and ribavirin raised cure rates for genotype 1 hepatitis C patients who did not respond to previous treatment, according ... ← Prev1234Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive